Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 4,342 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Time Management Clear all

Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer
Interventions: Pertuzumab, Trastuzumab, eribulin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Maternal Substance Use, Child Abuse and Neglect
Interventions: Mentalizing Therapy for Substance Using Mothers, Standard Parent Education for Substance Using Mothers; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Leptomeningeal Metastasis
Interventions: 186RNL; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: PTSD, Marital Relationship
Interventions: CBCT for PTSD, Prolonged Exposure; Behavioral
Lead sponsor: Toronto Metropolitan University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Fort Hood, Texas • Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Marginal Zone Lymphoma, Follicular Lymphoma
Interventions: Ublituximab, Umbralisib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pain, Chronic Pain, Musculoskeletal Pain
Interventions: Mindful Mapping, Serial Sevens; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions: Cinacalcet hydrochloride, Standard of Care; Drug
Lead sponsor: Amgen; Industry
Eligibility: 28 Days to 2189 Days
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 17
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: COVID-19
Interventions: AT-001; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy
Interventions: Capsaicin Topical Cream, Metoclopramide, Ondansetron, Lactated Ringers, Intravenous; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Heart Failure
Interventions: Ruboxistaurin; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 30 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Stress, Psychological, Stress, Physiological
Interventions: Stress Management and Resiliency Training (SMART) program; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Type 2 Diabetes, Vitamin B12 Deficiency, Neuropathy, Anemia
Interventions: Office visit intervention, Electronic Message Intervention; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: questionnaire administration, digital mammography, positron emission mammography; Other · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 35 Years and older · Female only
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn Disease, Pediatric Crohns Disease
Interventions: Azithromycin, Metronidazole, Standard of Care; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Postoperative Pain
Interventions: No choice given, Choice given, Ibuprofen, Acetaminophen, Gabapentin, Morphine (low), Morphine (med), Morphine (high); Other · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pain, Postoperative, Pain, Acute
Interventions: Auricular acupressure, Standard of care pain management; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bermuda Run, North Carolina

Conditions: Non-small Cell Lung Cancer Stage III
Interventions: Paclitaxel, Placebo for Veliparib, Carboplatin, Veliparib, Radiotherapy; Drug · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: La Jolla, California • Newark, Delaware • Chicago, Illinois + 8 more

Conditions: Solid Tumor, Lymphoma, Multiple Myeloma, Malignant Neoplasm, Mutation Abnormality
Interventions: Investigational Agent, Supportive Care Regimens, Next Gen Sequencing Report; Drug · Other · Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Curvature of Spine
Interventions: Tranexamic Acid; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Interventions: NOURISH Diet, Self-Selected Diet (Control); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pain
Interventions: Intervention Arm (STIMFIX); Other
Lead sponsor: STIMFIX; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Lake Havasu City, Arizona • Los Angeles, California • Clifton, New Jersey

Conditions: Type 1 Diabetes
Interventions: Observational; Other
Lead sponsor: University of Michigan; Other
Eligibility: 13 Years to 26 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cardiovascular Disease
Interventions: aerobic training, Wait list; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 20 Years to 45 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Higher Risk Myelodysplastic Syndromes
Interventions: bexmarilimab (1mg/kg), azacitidine, Placebo, bexmarilimab (3mg/kg); Drug
Lead sponsor: Faron Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Duarte, California • Aurora, Colorado • New Haven, Connecticut + 6 more

Search by objective public record fields.

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers

Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

5-minute Mindful Pain Management Strategy

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

Cardiovascular Effects of COVID-19

Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy

Ruboxistaurin in New York Heart Failure Classification III-IV Patients

A Mind-Body Intervention for Diabetes Management: A Pilot Study

Comparison of Two Pharmacist-led Population Management Approaches to Increase Monitoring of Vitamin B12 and Serum Creatinine Levels for Patients on Metformin

Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management

Nurse Initiated Acupressure for Pain Management

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Precision Medicine for Patients With Identified Actionable Mutations

The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

STIMFIX Trail Lead Anchor System for Dorsal Column Stimulator Trail Leads (SECURE Study)

Ecological Momentary Assessment Study of Adolescents and Young Adults With Type 1 Diabetes (EMA-T1D)

Exercise and Inflammation

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes